CN1320008C - Combination of acrylic ester containing ester group including partial radical of carboxyl group - Google Patents
Combination of acrylic ester containing ester group including partial radical of carboxyl group Download PDFInfo
- Publication number
- CN1320008C CN1320008C CNB2005100245885A CN200510024588A CN1320008C CN 1320008 C CN1320008 C CN 1320008C CN B2005100245885 A CNB2005100245885 A CN B2005100245885A CN 200510024588 A CN200510024588 A CN 200510024588A CN 1320008 C CN1320008 C CN 1320008C
- Authority
- CN
- China
- Prior art keywords
- methyl
- carboxyl
- ester
- monomer
- vinylformic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to an acrylic ester composition containing groups whose ester groups contain carboxyl group. The acrylic ester composition comprises the following components: (A) an acrylic ester whose ester groups contain the carboxyl group, (B) an acrylic ester or an acrylamide monomer, and (C) an optical initiating agent accounting 0.1% to 15% of the mass of the composition. The proportion of monomers A to monomers B can be arbitrarily regulated. Polymer thin films prepared from the composition can be used as controlled release films of a transdermal drug administering system TDDs. The physicochemical properties of the thin films can be finely regulated by regulating the species and the content of the monomers A and the monomers B in the composition so as to quickly prepare the controlled release films of the transdermal drug administering systems suitable for different kinds of medicine.
Description
Technical field
The present invention relates to a kind of photocurable monomer composition, be specifically related to a kind of ester group that comprises, can be used as the release-controlled film in the preparation transdermal delivery system partly with the composition of the acrylate of carboxylic group.
Background technology
Transdermal delivery system is meant that medicine discharges from the device of particular design, by complete skin absorption, enters the controlled release drug administration formulation of systemic blood system.Transdermal delivery system can be divided into two big class, i.e. membrane controlled release type and skeleton dispersion patterns basically.The membrane controlled release type transdermal delivery system is that medicine or transdermal absorption accelerator are rolled into the storage storehouse by release-controlled film or other controlled-release materials, by the character control release rate of drugs of release-controlled film or controlled-release material.Scopolamine (trade(brand)name Transderm-Scop), clonidine (trade(brand)name CatapresTTS) are film controlling types in the at present commercially available patch, and controlling diaphragm is a microporous polypropylene membrane; Pannonit (trade(brand)name Transderm-Nitro), fentanyl (trade(brand)name Duragesic), estradiol (trade(brand)name Estraderm), testosterone (trade(brand)name Androderm) are film controlling types, and release-controlled film is a polyethylene vinyl acetate; Nicotine (trade(brand)name trade(brand)name NicoDerm CQ) is a film controlling type, and controlling diaphragm is a polyethylene film.
At European patent No.46069, U.S. Patent No. 3,797 is described in 494 and utilizes microporous membrane control rate of releasing drug.The hole of film from 0.1 to 0.85, the curvature of film from 1 to 10, from 10 to 100 microns of film thicknesses, the film of usefulness has polypropylene, tetrafluoroethylene, polycarbonate, polyvinyl chloride, cellulose acetate, nitrocellulose, polyacrylonitrile etc. for example.Their shortcoming is that the kind of the microporous membrane that can Gong select for use is few, does not satisfy the formulation that more medicine is made percutaneous dosing.
In U.S. Patent No. 6,537, the Scopolamine Patch that is described among the 571B1, U.S. Patent No. 4,681, the Deponit TTS that is described in 584, used release-controlled film all is the multipolymer of ethene-vinyl acetate.Shortcoming is an organic solvent residue problem in the ethylene-vinyl acetate copolymer, and needs constantly to regulate the content of vinyl acetate between to for plastic to regulate the permeability of medicine.
At European patent No.1103260A2, in the clonidine patch that is described among the U.S. Patent No. 2004/0028726A1, utilize vinylformic acid-(2-ethyl) own ester, methyl methacrylate, vinylformic acid and vinyl acetate, Raolical polymerizable takes place, and the multipolymer that obtains can be controlled the release of medicine simultaneously as pressure-sensitive adhesive layer and bin-storing layer in the patch.Shortcoming is that Raolical polymerizable is influenced by several factors, factors such as the time that responds, temperature of reaction, raw material initial concentration, solvent, and also there is the residue problem of organic solvent in patch.
The film of in transdermal delivery system, using, generally speaking the release-controlled film kind lacks, and alternative little, this brings very big obstruction for the exploitation of percutaneous drug administration preparation.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, a kind of excellent curing performance that has is provided, can produce the monomer composition of the polymkeric substance that can be used for the release-controlled film in the transdermal delivery system.
For the shortcoming that the kind that solves release-controlled film in the existing transdermal delivery system lacks, the present invention finds that on extensive and deep research basis it is abundant to adopt a kind of special photo curable monomer composition just can obtain kind, the release-controlled film of excellent performance.Said composition comprises: (A) a kind of ester group of acrylate is partly with carboxylic group; (B) a kind of acrylate or acrylamide monomer; (C) a kind of light trigger accounts for 0.1%～15% of composition quality; The ratio of monomer A, B can be regulated arbitrarily in the composition.
The ester group of using among the present invention is partly with the acrylic ester monomer general formula CR of carboxylic group
2R
1=CR
3COOR
4Expression, wherein R
1, R
2, R
3Be any substituting group, comprise-H ,-CH
3,-C
6H
5,-CH=CH
2,-OH ,-COOH ,-OCH
3,-SO
3H ,-NH
2,-N (CH
3)
3Cl, R
4Be the substituting group that has carboxyl, comprise-CH
2OOH ,-(CH
2)
2COOH ,-(CH
2)
3COOH ,-(CH
2)
4COOH ,-(CH
2)
5COOH ,-(CH
2)
6COOH.The example of using among the present invention is the 2-carboxy ethyl acrylate, but is not limited only to this monomer, and all ester groups are partly with the acrylate of carboxylic group can be as this monomer potential alternative.Be exemplified below: (methyl) vinylformic acid-2-carboxyl ethyl ester, (methyl) vinylformic acid-3-carboxyl propyl ester, (methyl) vinylformic acid-2-carboxyl propyl ester, (methyl) vinylformic acid-positive butyl ester of 4-carboxyl, (methyl) vinylformic acid-positive butyl ester of 3-carboxyl, (methyl) vinylformic acid-positive butyl ester of 2-carboxyl, (methyl) vinylformic acid-2-carboxyl isobutyl ester, the just own ester of (methyl) vinylformic acid-6-carboxyl, the just own ester of (methyl) vinylformic acid-5-carboxyl, the just own ester of (methyl) vinylformic acid-4-carboxyl, the just own ester of (methyl) vinylformic acid-3-carboxyl, (methyl) vinylformic acid-just own ester of 2-carboxyl or the like, but be not limited to above listed monomer.
The acrylic ester monomer of using among the present invention can be used general formula CR
2R
1=CR
3COOR
4Expression, wherein R
1, R
2, R
3Can be any substituting group, such as-H ,-CH
3,-C
6H
5,-CH=CH
2,-OH ,-COOH ,-OCH
3,-SO
3H ,-NH
2,-N (CH
3)
3Cl or the like, but be not limited to above listed substituting group.R
4Substituting group can be the group of carboxyl substituted, and example is identical with the acrylate monomer that ester group is partly with carboxyl substituent.
R in the described acrylic ester monomer general formula
4Substituting group can be an alkyl also, and the example of using among the present invention is a vinylformic acid n-dodecane ester, but is not limited only to this monomer, all R
4Substituting group is that the acrylate of alkyl can be as this monomer potential alternative.Be exemplified below :-CH
3,-C
2H
5,-C
3H
7,-(CH
2)
3CH
3,-(CH
2)
4CH
3,-(CH
2)
5CH
3,-(CH
2)
7CH
3,-(CH
2)
11CH
3,-CH
2CH=CH
2Or the like, but be not limited to above listed substituting group.
R in the described acrylic ester monomer general formula
4Substituting group can be the group that ester group replaces, and the example of using among the present invention is 1, the 6-hexanediol dimethacrylate, but be not limited only to this monomer, all R
4Substituting group is that the acrylate of the group of ester group replacement can be as this monomer potential alternative.Be exemplified below :-CH
2OOCCH=CH
2,-(CH
2)
2OOCCH=CH
2,-(CH
2)
3OOCCH=CH
2,-(CH
2)
4OOCCH=CH
2,-(CH
2)
5OOCCH=CH
2,-(CH
2)
6OOCCH=CH
2,-(CH
2)
8OOCCH=CH
2,-(CH
2)
2OOCC (CH
3)=CH
2,-(CH
2)
3OOCC (CH
3)=CH
2,-(CH
2)
4OOCC (CH
3)=CH
2,-(CH
2)
5OOCC (CH
3)=CH
2,-(CH
2)
6OOCC (CH
3)=CH
2,-(CH
2)
8OOCC (CH
3)=CH
2Or the like, but be not limited to above listed substituting group.
R in the described acrylic ester monomer general formula
4Substituting group can be the group that hydroxyl replaces, and the example of using among the present invention is 2-hydroxyl-3-phenoxy group propyl acrylate, but is not limited only to this monomer, all R
4Substituting group is that the acrylate of the group of hydroxyl replacement can be as these two monomer potential alternatives.Be exemplified below :-CH
2OH ,-(CH
2)
2OH ,-(CH
2)
3OH ,-(CH
2)
4OH ,-(CH
2)
5OH ,-CH
2CH (OH) CH
3,-CH
2CH (OH) C
2H
5,-CH
2CH (OH) C
3H
7,-CH
2CH (OH) CH
2OC
6H
5,-C
2H
5CH (OH) CH
3,-C
2H
5CH (OH) C
2H
5,-C
3H
6CH (OH) CH
3,-C
3H
6CH (OH) C
2H
5,-C
3H
6(OH) CH
2OC
6H
5Or the like, but be not limited to above listed substituting group.
R in the described acrylic ester monomer general formula
4Substituting group can also be the group that alkoxyl group replaces, and the example of using among the present invention is a 2-butoxy ethyl propenoate, but is not limited only to this monomer, all R
4Substituting group is that the acrylate of alkoxyl group can be as this monomer potential alternative.Be exemplified below :-CH
2OCH
2CH
3,-CH
2O (CH
2)
2CH
3,-CH
2O (CH
2)
3CH
3,-CH
2O (CH
2)
4CH
3,-CH
2O (CH
2)
6CH
3,-CH
2O (CH
2)
8CH
3,-(CH
2)
2OCH
2,-(CH
2)
2OCH
2CH
3,-(CH
2)
2O (CH
2)
2CH
3,-(CH
2)
3O (CH
2)
2CH
3,-(CH
2)
2O (CH
2)
4CH
3Or the like, but be not limited to above listed substituting group.
Acrylamide monomer of the present invention can be used general formula CR
2R
1=CR
3CONR
4Expression, wherein R
1, R
2, R
3, R
4Define identical with acrylate monomer.The acrylamide monomers of using among the present invention is N-(1,1-dimethyl-3-oxo butyl)-acrylamide, but is not limited only to this monomer, and all acrylamide monomers can be as this monomer potential alternative.The acrylamide monomers example is exemplified below: (methyl) acrylamide, N, N-dimethyl (methyl) acrylamide, N-sec.-propyl (methyl) acrylamide, N-(butoxymethyl) (methyl) acrylamide, N-(methylol) (methyl) acrylamide, N-[(trishydroxymethyl) methyl] (methyl) acrylamide, N-[3-(dimethylamino) propyl group] (methyl) acrylamide or the like, but be not limited to above listed monomer.
Among the present invention can with light trigger comprise the initiator of the ultraviolet light polymerization that is useful on, as diphenyl peroxide ketone, 1-hydroxycyclohexylphenylketone, bitter almond oil camphor propyl ether, but not only be confined to these light triggers, all are for the UV-light sensitivity, and the light trigger that can trigger monomer be cured reaction is all unrestricted.
The polymeric film that preparation of compositions among the present invention obtains can be used as the release-controlled film in the transdermal delivery system (TDDs), by regulating kind and the content of monomer A, B in the composition, can finely tune the film physical and chemical performance, prepare the release-controlled film in the transdermal delivery system that is applicable to different pharmaceutical fast.Can in mixing solutions, add softening agent when adopting preparation of compositions release-controlled film of the present invention, comprise Citrate trianion, phthalate, sebacate etc., can further improve the physicals of release-controlled film.The present invention has widened the material category of the release-controlled film in the preparation transdermal delivery system, has enlarged the material range of choice.
Description of drawings
Fig. 1 is the 2-carboxy ethyl acrylate and get 30ul, the permeability experiment of the release-controlled film that ultraviolet light polymerization obtains after vinylformic acid n-dodecane ester mixes by quality at 5: 5.
Embodiment
Following examples are to the further specifying of technical solution of the present invention, and are not construed as limiting the invention.
Embodiment 1
The 2-carboxy ethyl acrylate is mixed by mass ratio with vinylformic acid n-dodecane ester at 5: 5, add the diphenyl peroxide ketone of 5% (w/w) again, dissolving, filter, get mixing solutions 30ul, be placed on the carrier substrates, coating is paved, and places ultraviolet light polymerization instrument completion of cure.
The cured film that obtains places the Franz diffusion cell of improvement, is wintergreen oil solution in the supply pool, and accepting in the pond is the phosphate buffered saline buffer of pH7.4.Utilize the rate of release of efficient liquid phase chromatographic analysis wintergreen oil.See Fig. 1: wintergreen oil is to the permeability experiment (correlation coefficient r=0.9874) of cured film, and cured film has linear controlled-release function to medicine as can be seen from Figure.
Embodiment 2
With 2-carboxy ethyl acrylate and 1, the 6-hexanediol dimethacrylate is pressed mass ratio mixing in 2: 8 by quality, adds the diphenyl peroxide ketone of 8% (w/w) again, dissolving is filtered, and gets mixing solutions 30ul, be placed on the carrier substrates, coating is paved, and places ultraviolet light polymerization instrument completion of cure.
Embodiment 3
The 2-carboxy ethyl acrylate is mixed by mass ratio with vinylformic acid-4-hydroxyl butyl ester at 2: 8, add the diphenyl peroxide ketone of 5% (w/w) again, dissolving, filter, get mixing solutions 30ul, be placed on the carrier substrates, coating is paved, and places ultraviolet light polymerization instrument completion of cure.
Embodiment 4
The 2-carboxy ethyl acrylate is mixed by mass ratio with 2-butoxy ethyl propenoate at 7: 3, add the 1-hydroxycyclohexylphenylketone of 0.1% (w/w) again, get mixing solutions 30ul, be placed on the carrier substrates, coating is paved, and places ultraviolet light polymerization instrument completion of cure.
Embodiment 5
With 2-carboxy ethyl acrylate and N-(1,1-dimethyl-3-oxo butyl)-acrylamide press mass ratio 1: 9 mixing by quality, the bitter almond oil camphor propyl ether that adds 15% (w/w) again, dissolving, filter, get mixing solutions 30ul, be placed on the carrier substrates, coating is paved, and places ultraviolet light polymerization instrument completion of cure.
Claims (5)
1, a kind of ester group that comprises is partly with the composition of the acrylate of carboxylic group, and it is characterized in that said composition comprises: (A) a kind of ester group of acrylate is partly with the monomer of carboxyl; (B) a kind of acrylate or acrylamide monomer; (C) a kind of light trigger that is used for ultraviolet light polymerization, account for composition quality O.1%～15%; The ratio of monomer A, B can be regulated arbitrarily in the composition;
The ester group of described acrylate is partly with the monomer general formula CR of carboxyl
2R
1=CR
3COOR
4Expression, wherein R
1, R
2, R
3Be any substituting group, R
4It is the substituting group that has carboxyl; Described acrylate monomer general formula CR
2' R
1'=CR
3' COOR
4' expression, described acrylamide monomer general formula CR
2' R
1'=CR
3' CONR
4' expression, wherein R
1', R
2', R
3' be any substituting group, R
4' be selected from carboxyl, alkyl, ester group, hydroxyl or alkoxyl group.
2,, it is characterized in that the ester group of described acrylate is partly with the R in the monomer of carboxyl, acrylate monomer and the acrylamide monomer general formula according to the composition of claim 1
1, R
2, R
3, R
1', R
2', R
3' be selected from independently of one another-H ,-CH
3,-C
6H
5,-CH=CH
2,-OH ,-COOH ,-OCH
3,-SO
3H ,-NH
2Or-N (CH
3)
3Cl.
3, according to the composition of claim 1, the ester group that it is characterized in that described acrylate is partly with the R in the monomer general formula of carboxyl
4Be selected from-CH
2COOH ,-(CH
2)
2COOH ,-(CH
2)
3COOH ,-(CH
2)
4COOH ,-(CH
2)
5COOH or-(CH
2)
6COOH.
4,, it is characterized in that the R in described acrylate monomer and the acrylamide monomer general formula according to the composition of claim 1
4' be selected from-CH
3,-C
2H
5,-C
3H
7,-(CH
2)
3CH
3,-(CH
2)
4CH
3,-(CH
2)
5CH
3,-(CH
2)
7CH
3,-(CH
2)
11CH
3,-CH
2CH=CH
2,-CH
2OH ,-(CH
2)
2OH ,-(CH
2)
3OH ,-(CH
2)
4OH ,-(CH
2)
5OH ,-CH
2CH (OH) CH
3,-CH
2CH (OH) C
2H
5,-CH
2CH (OH) C
3H
7,-CH
2CH (OH) CH
2OC
6H
5,-C
2H
5CH (OH) CH
3,-C
2H
5CH (OH) C
2H
5,-C
3H
6CH (OH) CH
3,-C
3H
6CH (OH) C
2H
5,-C
3H
6(OH) CH
2OC
6H
5,-CH
2OOCCH=CH
2,-(CH
2)
2OOCCH=CH
2,-(CH
2)
3OOCCH=CH
2,-(CH
2)
4OOCCH=CH
2,-(CH
2)
5OOCCH=CH
2,-(CH
2)
6OOCCH=CH
2,-(CH
2)
8OOCCH=CH
2,-(CH
2)
2OOCC (CH
3)=CH
2,-(CH
2)
3OOCC (CH
3)=CH
2,-(CH
2)
4OOCC (CH
3)=CH
2,-(CH
2)
5OOCC (CH
3)=CH
2,-(CH
2)
6OOCC (CH
3)=CH
2,-(CH
2)
8OOCC (CH
3)=CH
2,-CH
2COOH ,-(CH
2)
2COOH ,-(CH
2)
3COOH ,-(CH
2)
4COOH ,-(CH
2)
5COOH ,-(CH
2)
6COOH ,-CH
2OCH
2CH
3,-CH
2O (CH
2)
2CH
3,-CH
2O (CH
2)
3CH
3,-CH
2O (CH
2)
4CH
3,-CH
2O (CH
2)
6CH
3,-CH
2O (CH
2)
8CH
3,-(CH
2)
2OCH
2,-(CH
2)
2OCH
2CH
3,-(CH
2)
2O (CH
2)
2CH
3,-(CH
2)
3O (CH
2)
2CH
3Or-(CH
2)
2O (CH
2)
4CH
3
5, according to the composition of claim 1, the monomer that the ester group that it is characterized in that described acrylate is partly with carboxyl is selected from the 2-carboxy ethyl acrylate, (methyl) vinylformic acid-2-carboxyl ethyl ester, (methyl) vinylformic acid-3-carboxyl propyl ester, (methyl) vinylformic acid-2-carboxyl propyl ester, (methyl) vinylformic acid-positive butyl ester of 4-carboxyl, (methyl) vinylformic acid-positive butyl ester of 3-carboxyl, (methyl) vinylformic acid-positive butyl ester of 2-carboxyl, (methyl) vinylformic acid-2-carboxyl isobutyl ester, the just own ester of (methyl) vinylformic acid-6-carboxyl, the just own ester of (methyl) vinylformic acid-5-carboxyl, the just own ester of (methyl) vinylformic acid-4-carboxyl, just own ester of (methyl) vinylformic acid-3-carboxyl or the just own ester of (methyl) vinylformic acid-2-carboxyl; Described acrylate monomer is selected from vinylformic acid n-dodecane ester, 1,6-hexanediol dimethacrylate, 2-hydroxyl-3-phenoxy group propyl acrylate or 2-butoxy ethyl propenoate; Described acrylamide monomer is selected from N-(1,1-dimethyl-3-oxo butyl)-and acrylamide, (methyl) acrylamide, N, N-dimethyl (methyl) acrylamide, N-sec.-propyl (methyl) acrylamide, N-(butoxymethyl) (methyl) acrylamide, N-(methylol) (methyl) acrylamide, N-[(trishydroxymethyl) methyl] (methyl) acrylamide or N-[3-(dimethylamino) propyl group] (methyl) acrylamide.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100245885A CN1320008C (en) | 2005-03-24 | 2005-03-24 | Combination of acrylic ester containing ester group including partial radical of carboxyl group |
| PCT/CN2006/000509 WO2006099818A1 (en) | 2005-03-24 | 2006-03-24 | Light curable monomer compostion and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100245885A CN1320008C (en) | 2005-03-24 | 2005-03-24 | Combination of acrylic ester containing ester group including partial radical of carboxyl group |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1687158A CN1687158A (en) | 2005-10-26 |
| CN1320008C true CN1320008C (en) | 2007-06-06 |
Family
ID=35305200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100245885A Expired - Fee Related CN1320008C (en) | 2005-03-24 | 2005-03-24 | Combination of acrylic ester containing ester group including partial radical of carboxyl group |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1320008C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3210945B1 (en) * | 2016-02-29 | 2019-04-10 | Agfa-Gevaert | Method of manufacturing an etched glass article |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1045355A (en) * | 1988-12-22 | 1990-09-19 | Lts洛曼医疗***公司 | A kind ofly be used to produce to contain the method for calabar bean alkali as the Transcutaneous Therapeutic System of active component |
| CN1097635A (en) * | 1993-07-22 | 1995-01-25 | 计威康 | Medicine pressure sensing adhesive electrode |
| EP0913445A1 (en) * | 1997-10-28 | 1999-05-06 | National Starch and Chemical Investment Holding Corporation | Enhancer tolerant pressure sensitive adhesives for transdermal drug delivery |
| WO2003101433A1 (en) * | 2002-05-28 | 2003-12-11 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Plaster containing fentanyl |
| US20040131826A1 (en) * | 2003-01-06 | 2004-07-08 | General Electric Company | Radiation curable microstructure-bearing articles |
| CN1545408A (en) * | 2001-08-24 | 2004-11-10 | LTS��������ϵͳ�ɷݹ�˾ | Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups |
-
2005
- 2005-03-24 CN CNB2005100245885A patent/CN1320008C/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1045355A (en) * | 1988-12-22 | 1990-09-19 | Lts洛曼医疗***公司 | A kind ofly be used to produce to contain the method for calabar bean alkali as the Transcutaneous Therapeutic System of active component |
| CN1097635A (en) * | 1993-07-22 | 1995-01-25 | 计威康 | Medicine pressure sensing adhesive electrode |
| EP0913445A1 (en) * | 1997-10-28 | 1999-05-06 | National Starch and Chemical Investment Holding Corporation | Enhancer tolerant pressure sensitive adhesives for transdermal drug delivery |
| CN1545408A (en) * | 2001-08-24 | 2004-11-10 | LTS��������ϵͳ�ɷݹ�˾ | Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups |
| WO2003101433A1 (en) * | 2002-05-28 | 2003-12-11 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Plaster containing fentanyl |
| US20040131826A1 (en) * | 2003-01-06 | 2004-07-08 | General Electric Company | Radiation curable microstructure-bearing articles |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1687158A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06305953A (en) | Lamellar system for skin medical treatment with release ratio of delayed active substance, and its preparation | |
| KR101892764B1 (en) | Transdermal adhesive compositions, devices, and methods | |
| FR2560522A1 (en) | ADMINISTRATION FORM FOR PERCUTANEOUS ABSORPTION OF MEDICAMENTS, AND PROCESS FOR PREPARING THE SAME | |
| JP2005501111A (en) | Transdermal therapeutic system containing fentanyl or related substances | |
| EP1463492B1 (en) | Adhesive and binding agent for dermal or transdermal treatment systems | |
| PT2468274E (en) | Transdermal therapeutic system for application of an agent | |
| CN1939998B (en) | Acrylic pressure sensitive adhesives | |
| CN1320012C (en) | Combination containing acrylamide | |
| CN1320008C (en) | Combination of acrylic ester containing ester group including partial radical of carboxyl group | |
| JPS60185713A (en) | Percutaneous preparation and its production | |
| CN113616625B (en) | Long-acting transdermal patch of rivastigmine | |
| CN1320005C (en) | Combination of acrylic ester containing ester group including paraffin base | |
| CN1320009C (en) | Combination of acrylic ester containing ester group including partial radical of hydroxy group | |
| CA2583963C (en) | Method for the manufacture of pressure sensitive adhesives | |
| CN1326894C (en) | Combination of acrylic ester containing ester group including partial alkoxyl | |
| CN1320006C (en) | Combination of acrylic ester containing ester group including partial radical of ester group | |
| US5869089A (en) | Manufacturing method of programmable transdermal therapeutic system | |
| JP2003210566A (en) | Method of manufacturing adhesive molding mainly composed of crosslinked polymer | |
| JPS62228008A (en) | Medicinal pharmaceutical for external use | |
| JPS5823846B2 (en) | Hydrophilic medical components | |
| JPS5942314A (en) | Material for external use | |
| CN1615859A (en) | Nimodipine adhesive sheet | |
| Mhando et al. | Two-stage release of benzocaine from sunflower oil/gelatin emulsion films | |
| JPS6056686B2 (en) | Medical external parts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070606 Termination date: 20140324 |